UK Markets open in 3 hrs 6 mins

Veracyte, Inc. (VCYT)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
27.25+0.08 (+0.29%)
At close: 04:00PM EST
26.43 -0.82 (-3.01%)
After hours: 04:06PM EST

Veracyte, Inc.

6000 Shoreline Court
Suite 300
South San Francisco, CA 94080
United States
650 243 6300
https://www.veracyte.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees761

Key executives

NameTitlePayExercisedYear born
Ms. Bonnie H. AndersonCo-Founder & Exec. Chairwoman1.21M5.51M1958
Mr. Marc A. StapleyCEO & Director900.4kN/A1970
Ms. Rebecca ChambersExec. VP & CFO607.65kN/A1978
Dr. Giulia C. Kennedy Ph.D.Global Chief Scientific Officer & Chief Medical Officer691.33k1.9M1959
Dr. Tina S. Nova Ph.D.Pres of CLIA U.S. Bus.4.58kN/A1954
Ms. Beverly Jane Alley CPAVP & Corp. Controller398.01kN/A1963
Mr. Jonathan WygantVP & Chief Accounting OfficerN/AN/A1971
Mr. Steven FrenchSr. VP & Chief Information OfficerN/AN/AN/A
Ms. Annie McGuireSr. VP & Gen. CounselN/AN/A1980
Ms. Tracy MorrisVP of Global Corp. CommunicationsN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Corporate governance

Veracyte, Inc.’s ISS governance QualityScore as of 1 October 2022 is 6. The pillar scores are Audit: 3; Board: 4; Shareholder rights: 5; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.